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Summary
The contribution of BRCA1 and BRCA2 to inherited
breast cancer was assessed by linkage andmutation anal-
ysis in 237 families, each with at least four cases of breast
cancer, collected by the Breast Cancer Linkage Consor-
tium. Families were included without regard to the oc-
currence of ovarian or other cancers. Overall, disease
was linked to BRCA1 in an estimated 52% of families,
to BRCA2 in 32% of families, and to neither gene in
16% (95% confidence interval [CI] 6%–28%), sug-
gesting other predisposition genes. The majority (81%)
of the breast-ovarian cancer families were due to
BRCA1, with most others (14%) due to BRCA2. Con-
versely, the majority of families with male and female
breast cancer were due to BRCA2 (76%). The largest
proportion (67%) of families due to other genes was
found in families with four or five cases of female breast
cancer only. These estimates were not substantially af-
fected either by changing the assumed penetrance model
for BRCA1 or by including or excluding BRCA1 mu-
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tation data. Among those families with disease due to
BRCA1 that were tested by one of the standard screening
methods, mutations were detected in the coding se-
quence or splice sites in an estimated 63% (95% CI
51%–77%). The estimated sensitivity was identical for
direct sequencing and other techniques. The penetrance
of BRCA2 was estimated by maximizing the LOD score
in BRCA2-mutation families, over all possible pene-
trance functions. The estimated cumulative risk of breast
cancer reached 28% (95%CI 9%–44%) by age 50 years
and 84% (95% CI 43%–95%) by age 70 years. The
corresponding ovarian cancer risks were 0.4% (95% CI
0%–1%) by age 50 years and 27% (95% CI 0%–47%)
by age 70 years. The lifetime risk of breast cancer ap-
pears similar to the risk in BRCA1 carriers, but there
was some suggestion of a lower risk in BRCA2 carriers
!50 years of age.
Introduction
Mutations in a number of genes are now known to cause
susceptibility to breast and/or ovarian cancer. In the con-
text of high-risk families, the most important genes are
BRCA1 (MIM 113705 [http://www3.ncbi.nlm.nih.gov:
80/htbin-post/Omim/dispmim?113705]) and BRCA2
(MIM 600185 [http://www3.ncbi.nlm.nih.gov:80/htbin-
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post/Omim/dispmim?600185]). BRCA1was localized to
chromosome 17q by genetic linkage in 1990 (Hall et al.
1990) and subsequently was cloned in 1994 (Miki et al.
1994). Studies to date suggest that BRCA1 accounts for
the majority of families containing multiple cases of
breast and ovarian cancer (Easton et al. 1993; Narod et
al. 1995b), for less than half the families containing
breast cancer only (Easton et al. 1993), and for few
families that include male breast cancer cases (Stratton
et al. 1994). The risks conferred by BRCA1 have been
estimated both from linkage data (Easton et al. 1995)
and from the study of cancer incidence in carriers within
families with disease believed to be linked to the gene
(Ford et al. 1994). The cumulative risk of breast or ovar-
ian cancer in female carriers is estimated to be 180%
by age 70 years, although there is evidence that the ovar-
ian:breast cancer risk ratio varies between families, with
mutations toward the 5′ end of the gene conferring a
relatively higher ovarian cancer risk (Easton et al. 1995;
Gayther et al. 1995; Holt et al. 1996).
BRCA2 was localized to chromosome 13q in 1994
(Wooster et al. 1994) and was cloned in 1995 (Wooster
et al. 1995; Tavtigian et al. 1996). In their study of 15
families with evidence against linkage to BRCA1, Woo-
ster et al. (1994) estimated that disease was linked to
BRCA2 in 74% of families, providing preliminary evi-
dence that BRCA1 and BRCA2 together might account
for most high-risk breast cancer families. There is par-
ticularly clear evidence that BRCA1 and BRCA2 to-
gether are likely to account for the majority of high-risk
breast-ovarian cancer families. In a study of 145 breast-
ovarian cancer families, there were 10 families with
strong evidence against linkage to BRCA1 (multipoint
LOD scores !1.0); of these, 3 now have an identified
BRCA1 mutation, and 7 have an identified BRCA2 mu-
tation (Narod et al. 1995a, 1995b). A number of families
with evidence of linkage to 13q and/or with identified
BRCA2 mutations contain male cases. Easton et al.
(1997) have estimated the risks of cancer in BRCA2
mutation carriers in the two largest families showing
linkage in the original study. They found that the breast
cancer risk in females was similar to that conferred by
a BRCA1 mutation and estimated the risk in males to
be 6% by age 70 years. The increased risk of ovarian
cancer in mutation carriers appears to be lower in most
families than it is in families with a BRCA1 mutation.
Analyses of BRCA2 mutation data have provided evi-
dence that the risks of breast and ovarian cancer are
related to the position of the mutation: truncating mu-
tations in families with the highest risk of ovarian cancer
relative to breast cancer are clustered in a region in the
middle of exon 11 (Gayther et al. 1997).
The aims of this collaborative study were twofold:
first, to estimate the respective proportions of different
types of high-risk cancer families in which the disease is
due to BRCA1 and BRCA2 and to determine what pro-
portion of families might be due to unidentified genes;
and, second, to estimate the penetrance of BRCA2 in a
large data set. Groups in the Breast Cancer Linkage Con-
sortium (BCLC) were asked to submit linkage data on
markers flanking BRCA1 and BRCA2, for all families
containing at least four cases of either female breast can-
cer diagnosed at age !60 years or male breast cancer
diagnosed at any age. Information on BRCA1 mutation
testing, including method and outcome, was collected
on all families, and mutation details for families with
positive mutation tests for BRCA2 were provided. We
report here on the results of analyses of 237 families.
Families and Methods
Families
Families included in the study were all those that had
been typed, by the Breast Cancer Linkage Consortium
(BCLC), for linkage to BRCA1 and that contained at
least four cases of either female breast cancer diagnosed
at age !60 years or male breast cancer diagnosed at any
age, irrespective of any ovarian cancers in the family.
Two hundred thirty-seven families were included, 121
(51%) of which had been included in previous BCLC
studies. Sixty-seven of the 94 families with at least one
case of ovarian cancer but no male breast cancer (re-
ferred to subsequently as “breast-ovarian families”) had
been included in a BCLC study reported by Narod et
al. (1995b). Twelve of the 26 families with at least one
case of male breast cancer were part of a study by Strat-
ton et al. (1994). Only 42 of the 117 families with no
ovarian or male breast cancer were in the first BCLC
study, which examined linkage to BRCA1 (Easton et al.
1993).
One hundred eighty of the families had been tested
for a BRCA1mutation, including 67 that had been tested
by direct sequencing. Mutations within the BRCA1 cod-
ing sequence had been reported in 64 families. Thirty-
six families were known to have a BRCA2 mutation.
Genetic Markers
All families included in this study had been typed for
markers flanking BRCA1. For the majority of families,
D17S579 (Hall et al. 1992) and D17S250 (Weber et al.
1990) typings were available. For a small number of
families, data were unavailable for these two markers,
and data for other markers in the region—in particular,
THRA1 (Bowcock et al. 1993) and D17S855 (Gyapay
et al. 1994)—were used. The 17q marker typings had
not been scored consistently across the families, so, in
the analysis, each marker was coded as a system of
equally frequent alleles (with the number of alleles cho-
sen to reflect the observed polymorphism of the marker).
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One hundred seventy-seven families had, in addition,
been typed for markers D13S260 and D13S267, which
flank BRCA2 (Wooster et al. 1994). Thirty-five families
that had not been typed for linkage to BRCA2 had a
mutation in the BRCA1 gene. An additional six families
showed strong evidence for linkage to BRCA1 (LOD
score 11.0). The remaining 19 families had not been
studied for linkage to BRCA2, either because the inves-
tigating group concerned had no remaining DNA from
critical family members or because it was not feasible
because of other reasons. 13q marker typings were
scored consistently across families, and the allele fre-
quencies used for analysis were taken from the Genome
Database, in which frequencies are based on 56 CEPH
chromosomes.
Statistical Methods
Estimating the proportions of families in which the
disease is due to BRCA1 and BRCA2.—The proportions
of families with disease due to BRCA1 and BRCA2 were
estimated by computation of heterogeneity LOD scores.
In our first analysis, we assumed that the same breast
cancer risks were conferred by mutations in BRCA1,
BRCA2, and other susceptibility genes. These risks were
based on a “standard” genetic model for breast cancer,
derived by Claus et al. (1991), from the Cancer and
Steroid Hormone Study (the “CASH” model). Under
this model, susceptibility to breast cancer in females is
conferred by an autosomal dominant gene with popu-
lation frequency .003, and the risk of breast cancer at
age !70 years is 67% in carriers. The penetrance for
ovarian cancer in carriers of the susceptibility gene was
derived by assuming a constant relative risk with age
and an estimated cumulative risk of 10% by age 60 years
(Claus et al. 1993).
In our second analysis, BRCA1 was assumed to confer
a penetrance higher than that in the CASH model, as
had been suggested by previous studies: a cumulative
breast cancer risk in females of 49% by age 50 years
and 71% by age 70 years and a cumulative ovarian
cancer risk of 16% by age 50 years and 42% by age 70
years (Easton et al. 1993; Narod et al. 1995b). BRCA2
and any other genes were still assumed to confer the
CASH risks. In the present analysis, we estimate the
relative frequency of mutations in BRCA1, BRCA2, and
other genes and use these estimates to derive the pro-
portions of families in which the disease is linked to each
gene. Computational details are given in Appendix A.
A small number of families ( ) were not typedn  37
for BRCA2 markers, despite having LOD scores !1.0 at
BRCA1, and, in some cases ( ), this was relatedn  18
to having a BRCA1 mutation. This could lead to some
bias in the estimates derived by the methods described
above, which do not incorporate BRCA1 mutation
status. We therefore performed some further analyses,
in which the BRCA1 mutation status, as well as the
linkage data, were used to estimate the proportion of
families in which the disease is due to BRCA1 and
BRCA2. In order to do this, an extra parameter, d, was
introduced, to model the probability of identifying a
BRCA1 mutation when one existed (see Appendix B).
The sensitivity parameter d is likely to depend on the
method used for detection of mutations. The method of
detection here refers to the method used initially to
screen the coding sequence and splice sites for altera-
tions; all investigating groups used direct sequencing to
identify the precise mutation in individuals with screen-
ing abnormalities. All groups except two (CRC and
ICRF, where the testing was split between more than one
laboratory) used one technique consistently. We first es-
timated the sensitivity of completely sequencing the cod-
ing sequence of the BRCA1 gene (Miki et al. 1994) of
at least one affected individual (d1) and the sensitivity of
the other genomic screening techniques taken together
(d2)—namely, constant-denaturating gel electrophoresis
(CDGE; Stoppa-Lyonnet et al. 1997), confirmation-sen-
sitive gel electrophoresis (CSGE; Ganguly et al. 1993) ,
direct screening for deletions and inversions, in combi-
nation with protein-truncation analysis (DSDI/PTT;
Hogervorst et al. 1995; Peelen et al. 1997), SSCP-het-
eroduplex analysis (SSCP-HA; Gayther et al. 1996), and
SSCP alone. Since d1 and d2 were estimated identically,
subsequent analyses were based on a single estimate for
d, to represent the sensitivity of mutational analysis by
any of these methods.
Estimating the penetrance of BRCA2.—The basic
method used for estimation of the age-specific risks con-
ferred by BRCA2 was to maximize the LOD score over
different values of the penetrance function (Easton et al.
1993). This method is equivalent to maximizing the like-
lihood conditional on all phenotypic data and hence is
free from the ascertainment bias caused by family se-
lection on the basis of multiple affected individuals. In
the first analysis, we used the families with an identified
mutation in BRCA2. We then repeated the analyses, us-
ing all families with six or more cases of either female
breast cancer at age 60 years or male breast cancer at
any age, assuming that all these families were due to
either BRCA1 or BRCA2. The BRCA1 risks were held
fixed at the values estimated elsewhere (Easton et al.
1993; Narod et al. 1995b). In addition to the BRCA2
risks, an extra parameter was estimated, corresponding
to the proportion of all high-risk mutations that are
BRCA1mutations. Further details are given in Appendix
C.
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Table 1
Heterogeneity Analysis under the CASH Model
FAMILY GROUP
NO. OF
FAMILIES
PROPORTION (95% CI) OF FAMILIES
WITH DISEASE LINKED TO:
LOD
SCOREBRCA1 BRCA2 Other
All families:
Four or five breast cancers, male or female 154 .55 (.40–.70) .12 (.00–.29) .33 (.14–.53) 19.28
Six or more breast cancers 83 .46 (.32–.60) .50 (.35–.65) .04 (.00–.17) 67.44
Overall 237 .52 (.42–.63) .35 (.24–.46) .13 (.03–.25) 84.08
All families, no males:
Four or five breast cancers 140 .61 (.44–.76) .08 (.00–.25) .31 (.12–.53) 19.90
Six or more breast cancers 71 .50 (.34–.65) .44 (.28–.61) .06 (.00–.21) 50.40
Overall 211 .57 (.45–.68) .28 (.18–.40) .15 (.04–.28) 68.13
Male breast cancer 26 .19 (.01–.47) .77 (.43–.97) .04 (.00–.42) 18.03
Breast-ovarian cancer, no males:
One ovarian cancer 42 .69 (.46–.89) .19 (.04–.41) .12 (.00–.33) 15.11
Two or more ovarian cancers 52 .88 (.69–.98) .12 (.02–.31) .00 (.00–.15) 44.07
Overall 94 .80 (.66–.92) .15 (.05–.28) .05 (.00–.17) 58.57
Female breast cancer only:
Four or five breast cancers 83 .32 (.10–.55) .09 (.00–.35) .59 (.26–.89) 2.29
Six or more breast cancers 34 .19 (.04–.41) .66 (.39–.88) .15 (.00–.44) 14.18
Overall 117 .28 (.13–.45) .37 (.20–.56) .35 (.14–.57) 14.47
Results
Proportions of Families with Disease Due to BRCA1
and BRCA2
Tables 1 and 2 summarize the results of the hetero-
geneity analyses using BRCA 1 and BRCA2 linkage data
only. In table 1 the estimated proportions of families
linked to each gene are given, with the CASH model
being assumed for all genes. Overall, an estimated 52%
of families have disease due to BRCA1, and 35% have
disease due to BRCA2. There is significant evidence of
families with disease not linked to either gene ( 2x 1
; ), although the estimated proportion of8.57 P  .003
families with disease due to other genes is only 13%. In
families with fewer than six cases of breast cancer, the
proportion of families with disease due to other genes
(33%) is higher than it is in families with six or more
cases (4%), in which the evidence for other genes is, in
fact, not significant. In the majority (77%) of families
with one or more cases of male breast cancer, the disease
is estimated to be due to BRCA2, with a smaller pro-
portion (19%) estimated as being due to BRCA1. The
evidence for other susceptibility genes is not significant,
although the upper confidence limit on the remaining
proportion of families is 42%. Of the families with
breast and ovarian cancer but with no male case, the
large majority of families are estimated to have disease
due to BRCA1 (80%), with a smaller proportion (15%)
estimated to be due to BRCA2. The evidence for other
genes is weak in this group of families, the upper con-
fidence limit for the proportion of disease due to other
genes being 17%. Among the 117 families with female
breast cancer only, the proportions of families estimated
to have disease due to BRCA1, BRCA2, and other genes
were similar (28%, 37%, and 35%, respectively). The
estimated proportion of families with disease due to
other genes was higher in families with fewer than six
cases (59%) than in families with six or more cases
(15%, with a lower confidence limit of 0%). Interest-
ingly, in families with six or more cases of breast cancer
and no ovarian cancer, the largest proportion of disease
was due to BRCA2 (66%, compared with 19% due to
BRCA1).
In table 2 the estimated proportions of high- risk mu-
tations, as well as the corresponding estimated propor-
tions of families, attributable to each gene are given,
under the assumption that BRCA1 confers the risks es-
timated in previous consortium analyses whereas
BRCA2 and other genes confer risks given by the CASH
model. Families containing male breast cancers have
been excluded from table 2, since (1) the penetrance in
males is uncertain for all genes and (2) estimation of the
proportion of high-risk mutations attributable to each
gene is strongly dependent on the assumed penetrances.
In general, the estimated proportions of families with
disease due to each of the genes is very similar in the
two analyses, strengthening the support for these esti-
mates. The largest difference is in the families with six
or more cases of female breast cancer only, where the
estimated proportion due to BRCA1 is higher (29% vs.
19%) and the proportion due to other genes is, corre-
spondingly, lower (5% vs. 15%), when a higher pene-
trance for BRCA1 is assumed. There is stronger evidence
for other predisposition genes in the breast-ovarian can-
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Table 2
Heterogeneity Analysis Allowing BRCA1 to Confer Higher Penetrance
FAMILY GROUP
NO. OF
FAMILIES
PROPORTION (95% CI) OF HIGH-RISK
MUTATIONS AND FAMILIESa
LOD
SCOREBRCA1 BRCA2 Other
All families, no males:
Four or five breast cancers 140 .52 (.31–.73)
.56 (.42–.70)
.06 (.00–.24)
.05 (.00–.19)
.42 (.19–.67)
.39 (.21–.56)
23.04
Six or more breast cancers 71 .39 (.22–.58)
.50 (.45–.55)
.51 (.32–.70)
.42 (.34–.49)
.10 (.00–.28)
.08 (.00–.17)
55.65
Overall 211 .47 (.33–.62)
.54 (.46–.61)
.31 (.18–.45)
.27 (.19–.35)
.22 (.09–.38)
.19 (.10–.30)
76.11
Breast-ovarian cancer, no males:
One ovarian cancer 42 .60 (.31–.86)
.67 (.52–.81)
.20 (.04–.47)
.16 (.07–.30)
.20 (.03–.47)
.17 (.05–.30)
13.58
Two or more ovarian cancers 52 .42 (.19–.77)
.80 (.72–.89)
.52 (.10–.81)
.18 (.05–.27)
.06 (.00–.52)
.02 (.00–.15)
46.73
Overall 94 .52 (.31–.76)
.74 (.66–.83)
.29 (.10–.52)
.16 (.08–.24)
.19 (.03–.42)
.10 (.03–.19)
59.99
Female breast cancer only:
Four or five breast cancers 83 .43 (.15–.69)
.36 (.16–.55)
.07 (.00–.30)
.08 (.00–.28)
.50 (.20–.84)
.56 (.28–.83)
2.75
Six or more breast cancers 34 .35 (.11–.63)
.29 (.19–.38)
.61 (.33–.85)
.66 (.52–.76)
.04 (.00–.32)
.05 (.00–.25)
15.66
Overall 117 .42 (.23–.62)
.35 (.24–.47)
.32 (.16–.49)
.36 (.22–.48)
.26 (.07–.48)
.29 (.10–.47)
16.21
a Within each table cell, the underlined entry is the proportion of high-risk mutations, and the entry
below it is the proportion of families.
cer families in this analysis, although the estimated pro-
portion is still small (10%), and, in families with at least
two cases of ovarian cancer, there is still no significant
evidence of other predisposition genes.
The proportions of high-risk mutations that occur in
each gene should not depend on family type, so the es-
timates should be consistent across subgroups of fami-
lies, providing that the penetrances of the genes are well
estimated. If the families with male cases are excluded,
an estimated 47% of high-risk mutations occur in
BRCA1 and 31% occur in BRCA2, leaving 22% of mu-
tations in unidentified genes. The estimates do not differ
significantly between the breast-ovarian cancer families
and the families with female breast cancer only ( ;2x 2
) or between families with only one ovarian can-P  .81
cer and families with two or more ovarian cancers
( ; ). Estimates do differ, however, be-2x  1.47 P  .482
tween families with fewer than six cases of female breast
cancer and families with six or more cases ( 2x 2
; ), reflecting the difference seen in the11.88 P  .003
families without ovarian cancer, in which 7% of mu-
tations are attributed to BRCA2 and 50% are attributed
to other genes if there are fewer than six cases in the
family, compared with 61% and 4%, respectively, if
there are six or more cases ( ; ).2x  10.13 P  .0062
Analysis Including BRCA1 Mutation Data
One hundred eighty of the families were tested for
mutations in BRCA1, the majority by direct sequencing
(67 families) or by one or more of the following: CDGE,
CSGE, DSDI/PTT, SSCP-HA, and SSCP alone (106 fam-
ilies). One family had been tested by PTT only, and six
families had been analyzed by SSCP across a portion of
the gene.
In the initial heterogeneity analyses incorporating
BRCA1 testing information, the estimated proportion of
mutations identified by direct sequencing was allowed
to differ from the proportion identified byCDGE,CSGE,
DSDI/PTT, SSCP-HA, or SSCP. Both the family tested
by PTT and the six families only partially analyzed were
assumed not to have been tested. Across all families, the
estimated sensitivity of sequencing under the CASH
model was .64 (95% CI .45–.84), which was the same
as the estimated sensitivity for the other methods (.64
[95%CI .49-.80]). The estimated proportions of families
with disease due to BRCA1 (52% [95%CI 42%–62%]),
BRCA2 (32% [95% CI 22%-43%]), and other genes
(16% [95%CI 6%-28%]) were almost identical to those
obtained by use of linkage data only (see table 1 ). We
subsequently reanalyzed the data, assuming a single sen-
sitivity parameter for all the standard screeningmethods.
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Table 3
Heterogeneity Analysis under the CASH Model Incorporating BRCA1 Mutation Data
FAMILY GROUP
NO. OF FAMILIES
PROPORTION (95% CI) OF LINKED
FAMILIES
PROPORTION
(95% CI) OF
MUTATIONS
IDENTIFIEDaTotal
Tested for
BRCA1
Mutation
Positive BRCA1 BRCA2 Other
All families:
Four or five breast cancers, male or female 154 121 40 .50 (.36–.65) .13 (.0–.28) .37 (.19–.56) .64 (.46–.84)
Six or more breast cancers, male or female 83 59 24 .50 (.37–.63) .45 (.31–.58) .05 (.00–.17) .69 (.50–.86)
Overall 237 180 64 .52 (.42–.62) .32 (.22–.43) .16 (.06–.28) .63 (.51–.77)
All families, no males:
Four or five breast cancers 140 114 39 .54 (.40–.69) .08 (.00–.23) .38 (.19–.58) .63 (.45–.82)
Six or more breast cancers 71 52 23 .55 (.41–.69) .38 (.24–.53) .07 (.00–.21) .70 (.51–.87)
Overall 211 166 62 .55 (.45–.66) .26 (.16–.37) .19 (.08–.31) .64 (.51–.77)
Male breast cancer 26 14 2 .16 (.02–.48) .76 (.43–.97) .08 (.00–.44) .67 (.09–1.0)
Breast-ovarian cancer, no males:
One ovarian cancer 42 39 20 .69 (.50–.86) .21 (.06–.40) .10 (.00–.28) .79 (.56–.96)
Two or more ovarian cancers 52 45 26 .91 (.76–.99) .09 (.01–.24) .00 (.00–.11) .62 (.46–.77)
Overall 94 84 46 .81 (.68–.91) .14 (.05–.26) .05 (.00–.16) .68 (.55–.81)
Female breast cancer only:
Four or five breast cancers 83 63 11 .28 (.11–.50) .05 (.00–.29) .67 (.35–.89) .61 (.29–1.0)
Six or more breast cancers 34 19 5 .21 (.08–.42) .60 (.34–.83) .19 (.01–.45) 1.0 (.41–1.0)
Overall 117 82 16 .26 (.13–.42) .32 (.17–.50) .42 (.21–.62) .68 (.38–1.0)
a By sequencing, CDGE, CSGE, DSDI/PTT, SSCP-HA, SSCP, or PTT.
Table 3 describes the heterogeneity results under the
CASH model with the incorporation of the BRCA1 mu-
tation data. The proportion of mutations identified re-
fers here to a single estimate for all methods. PTT alone
(which had been used in one family) was assumed to be
as sensitive as sequencing, CDGE, CSGE, DSDI/PTT,
SSCP-HA, or SSCP, and the partial screening by SSCP,
which was used in six families, was assumed to be 25%
as efficient as the other methods. The results in table 3
show that, when mutation data are incorporated, the
estimated proportions of families with linkage to each
gene are almost identical to those estimated from linkage
data alone. The estimated proportions of mutations be-
ing identified is consistent, in all family types, with the
overall estimate of 63% (95% CI 51%–77%). We also
repeated the analyses under the alternative model, al-
lowing the risks conferred by BRCA1 to be higher than
those conferred by BRCA2 or the other genes; again,
incorporating the mutation data had no influence on the
heterogeneity estimates (data not shown).
Penetrance of BRCA2
The overall penetrance of BRCA2 was estimated in
the 32 families in which a BRCA2 mutation was found
and in which D13S267 typing was available and infor-
mative. Table 4 gives the risks of breast or ovarian cancer
in these families, obtained by maximizing the LOD score
over the age-specific incidence rates of disease. The es-
timated overall penetrance is 29% (95% CI 9%–44%)
by age 50 years and 88% (95% CI 48%–97%) by age
70 years. Most of this risk is due to breast cancer; among
mutation carriers, there are no cases of ovarian cancer
at age !40 years and only two cases of ovarian cancer
at age !50 years. The estimated breast cancer risk in
this group is 28% (95% CI 9%–44%) by age 50 years
and 84% (95% CI 43%–95%) by age 70 years. The
corresponding ovarian cancer risks are 0.4% (95% CI
0%–1%) by age 50 years and 27% (95% CI 0%–47%)
by age 70 years.
Table 5 shows the risks obtained for BRCA2mutation
carriers if families with at least six cases of breast cancer
(females at age !60 years or males at any age) are at-
tributed to BRCA1 or BRCA2. (One family was ex-
cluded from this analysis, because of a consanguineous
relationship that could not be ignored.) In the age group
40–59 years, the estimated overall risks and breast can-
cer risks are higher than the risks in the mutation fam-
ilies, although the differences do not reach statistical
significance (difference in overall cancer risks by age 50
years [ ]; difference by age 60 years [ ]),P  .11 P  .50
and the risks by age 70 years are very similar in the two
analyses (86% overall vs. 88% overall). The risks pre-
viously estimated for BRCA1 are also given, for com-
parison. The estimated risks for BRCA2 are slightly
lower by ages 40 years and 50 years and are slightly
higher by age 70 years, but they are not significantly
different at any age. When only the mutation families
are considered, the estimated BRCA2 risk, up to age 50
years, is more markedly lower than is the BRCA1 risk,
although, again, the risks by age 70 years are similar.
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Table 4
Incidence and Cumulative Risks of Breast and Ovarian Cancer in BRCA2 Mutation Carriers
AGE
GROUP
(YEARS)
BREAST AND OVARIAN CANCER BREAST CANCER ONLY OVARIAN CANCER ONLY
Incidence
Cumulative
Risk (95% CI) No. Incidence
Cumulative
Risk (95% CI) No. Incidence
Cumulative
Risk (95% CI)
20–29 .000633 .006 (0–.019) 7 .000633 .006 (0–.019) 0 .00 .00
30–39 .0118 .12 (0–.24) 61 .0118 .12 (0–.24) 0 .00 .00
40–49 .0215 .29 (.090–.44) 99 .0210 .28 (.090–.44) 2 .000425 .004 (0–.011)
50–59 .0390 .52 (.24–.70) 44 .0318 .48 (.22–.65) 10 .00722 .074 (0–.15)
60–69 .142 .88 (.48–.97) 20 .118 .84 (.43–.95) 4 .0236 .27 (0–.47)
NOTE.—All data are for first cancers; the number exclude second primaries and known noncarriers of mutation or “linked”-haplotype.
Table 5
Estimated Penetrance of BRCA2 and Comparison with Penetrance of BRCA1
AGE
(YEARS)
PENETRANCE (95% CI)
BRCA2
32 Families with
BRCA2 Mutation
82 Families with Six or
More Breast Cancersb BRCA1a
Breast and
Ovarian
––Cancer
Breast Cancer
––Only
Breast and
Ovarian
––Cancer
Breast Cancer
––Only
Breast and
Ovarian
––Cancer
Breast Cancer
––Only
30 .006 (0–.019) .006 (0–.19) .046 (.004–.086) .046 (.004–.086) .036 (0–.14) .036 (.0–.14)
40 .12 (0–.24) .12 (0–.24) .12 (.048–.18) .12 (.048–.18) .18 (0–.36) .18 (.0–.35)
50 .29 (.090–.44) .28 (.090–.44) .46 (.31–.57) .45 (.31–.57) .57 (.33–.73) .49 (.28–.64)
60 .52 (.24–.70) .18 (.22–.65) .61 (.39–.76) .59 (.37–.73) .75 (.53–.87) .64 (.43–.77)
70 .88 (.48–.97) .84 (.43–.95) .86 (.25–.98) .83 (.27–.96) .83 (.65–.92) .71 (.53–.82)
a Source: Narod et al. (1995b).
b Proportion of BRCA2 mutations is .84 (95% CI .56–1.0) when it is assumed that BRCA1 and BRCA2 account for cancers in all families.
Corresponding proportion of families with BRCA2 mutations is .50 (95% CI .39–1.0).
Table 6 provides the risks for the BRCA2 mutation
families, according to mutation location. The gene has
been divided into three regions, the middle region being
the ovarian cancer–cluster region (OCCR) suggested by
Gayther et al. (1997). One family with a missense mu-
tation was excluded from this analysis. The estimated
breast cancer risks appear to be similar in all three
groups. The estimated ovarian cancer risk is, however,
higher in the OCCR, in agreement with the results of
Gayther et al. (1997), although the confidence limits are
very wide.
Discussion
This report describes the analysis of the largest col-
lection of breast cancer families in the world, for linkage
to BRCA1 and BRCA2. Two hundred thirty-seven fam-
ilies with four or more cases of either female breast can-
cer diagnosed at age !60 years or male breast cancer at
any age were contributed by 21 investigating groups
from nine countries. All families were typed with genetic
markers flanking BRCA1, and 177 families were typed
with genetic markers flanking BRCA2.
As had been suggested by other BCLC studies, almost
all breast-ovarian cancer families appear to be compat-
ible with linkage to BRCA1 or BRCA2 (Narod et al.
1995a, 1995b). Only 2 families (CJP3 and MDC60) of
the 94 breast-ovarian cancer families had multipoint
LOD scores of !1.0 at both loci; both these families
had been screened for germ-line BRCA1 mutations, al-
though neither was sequenced, and neither had been
tested for a mutation in BRCA2. Each of these two fam-
ilies had only one case of ovarian cancer. One of these
families (MDC60) recently has been shown, tentatively,
to have disease linked to markers on chromosome 8p
(Seitz et al. 1997), a location for a breast can-
cer–susceptibility gene first suggested by Kerangueven et
al. (1995). There was very little evidence for another
predisposition gene in the 52 families containing two or
more cases of ovarian cancer; under the CASH model
the point estimate for the proportion of remaining fam-
ilies was 0.0, and under the model allowing BRCA1 to
confer a higher penetrance it was 2%.
This study has confirmed that the large majority of
families containing both male and female breast cancer
have disease that is due to BRCA2. In slight contrast to
previous linkage studies (Stratton et al. 1994), there is
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Table 6
Cumulative Risks of Breast and Ovarian Cancer in BRCA2 Mutation Carriers, by Mutation Location
AGE
CUMULATIVE RISK (95%CI)
Exons 1–10 and 11, Nucleotides
1–1034
Exon 11, Nucleotides
1035–6629
Exon 11, Nucleotides 6630–end
and Exons 12–23
Breast Cancer Ovarian Cancer Breast Cancer Ovarian Cancer Breast Cancer Ovarian Cancer
30 .0011 (0–.0042) 0 .016 (0–.10) 0 .017 (0–.071) 0
40 .14 (0–.34) 0 .090 (0–.30) 0 .10 (0–.25) 0
50 .26 (0–.47) .0036 (0–.12) .27 (0–.62) 0 .32 (0–.56) .0063 (0–.021)
60 .41 (.053–.63) .053 (0–.13) .47 (0–.82) .24 (0–.64) .60 (.12–.82) .052 (0–.13)
70 .82 (0–.97) .26 (0–.53) .83 (0–.99) .76 (0–.98) .78 (0–.97) .052 (0–13)
now clear evidence, both from linkage data and from
mutation data (two families had identified mutations),
that a proportion of these families are the result of
BRCA1 mutations; 16% (95% CI 2%–48%) of families
with a male case were estimated to be due to BRCA1.
Of the seven families with two or more cases of male
breast cancer, four had BRCA2 mutations, and data for
one additional family were consistent with linkage to
BRCA2 (LOD score 0.8), whereas data for the remaining
two families were consistent with linkage to BRCA1 but
not to BRCA2. The most likely interpretation of these
findings is that BRCA1 mutations do confer an increased
risk of male breast cancer but that the risk is lower than
the risk conferred by BRCA2.
Heterogeneity results for the families containing only
female breast cancer are of particular interest because
the majority of families in the population are of this
type, and the BCLC data on these families have ex-
panded enormously since our first study (Easton et al.
1993). In the current study there were 117 families with
no ovarian or male breast cancers. We estimate that in
∼60% of these families the disease is likely to be due to
a BRCA1 mutation or a BRCA2 mutation, regardless of
the analysis model used. Of the families with six or more
cases of female breast cancer, 21% are estimated to have
disease that is due to BRCA1, and 60% are estimated
to have disease that is due to BRCA2, leaving 19% due
to other genes, when the CASH model is assumed for
all genes and the BRCA1 mutation data are incorpo-
rated, with similar estimates in the other analyses. There
were no large families with only female breast cancer
that had LOD scores !1.0 at both BRCA1 and
BRCA2. In the group of families with four or five cases
of female breast cancer, the proportions of families with
disease attributable to BRCA1, BRCA2, and other genes
are 28%, 5%, and 67%, respectively. The low propor-
tion of families with four or five cases of female breast
cancer that is due to BRCA2, as compared with the
proportion of families with six or more cases due to it,
may be due partly to chance, particularly since the latter
group contains only 34 families. Both the low estimate
of the proportion of families with only breast cancer due
to BRCA1 and the slightly lower estimate for the pro-
portion of the larger families with only breast cancer
due to it are likely to be due to the significant ovarian
cancer risk associated with BRCA1, although it is worth
noting that a BRCA1 mutation was identified in 5 of
the 34 families with six or more breast cancers and no
ovarian cancer. The most important conclusion from this
analysis is that a large proportion, perhaps the majority,
of families with five or fewer cases of breast cancer and
no ovarian or male breast cancer cases are not due to
either BRCA1 or BRCA2. This is also indicated by the
recent study by Serova et al. (1997), who performed
mutation screening of BRCA1 and BRCA2 in 31 site-
specific breast cancer families (7 of which have been
included in the present study) and found mutations in
only 8 of them. Similar results also were observed by
Ha˚kansson et al. (1997) and Schubert et al. (1997). A
particular value of the current study, however, in addi-
tion to its much larger size, is that its results are based
primarily on linkage and hence are not dependent on
the sensitivity of the mutation testing. The fact that the
proportion of families without linkage is much larger
among families with fewer than six cases is consistent
with the hypothesis that susceptibility alleles in other
breast cancer genes confer risks lower than those con-
ferred by BRCA1 or BRCA2 but are, correspondingly,
more common in the population. The other known sus-
ceptibility genes—such as TP53, ATM, the mismatch-
repair genes, the newly identified PTEN gene involved
in Cowden syndrome (Liaw et al. 1997), and the gene(s)
responsible for Peutz-Jeghers syndrome (Hemminki et
al. 1997)—are unlikely to explain the high frequency of
disease in an important fraction of these families. We
conclude that other susceptibility genes responsible for
a large fraction of familial breast cancer remain to be
identified. Note that the present study did not examine
linkage or mutation data in families with fewer than
four cancer cases, so we cannot make any direct estimate
of the contribution of BRCA1 and BRCA2 to families
with two or three cases (in practice, by far the largest
group), but, by extrapolation from the results in this
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study, one would predict that their contribution would
be relatively minor.
Overall, the heterogeneity analyses suggest that, in the
western European and North American populations
studied, BRCA1 is a slightly more common cause of
cancer in high-risk families than is BRCA2. There may,
however, be important local variations due to founder
effects, most notably in Iceland, where, in six of the eight
high-risk families, the disease is due to a single BRCA2
mutation. Moreover, the results do not imply that
BRCA1 mutations are more common in lower-risk fam-
ilies, breast cancer cases, or the general population. In
fact, if the penetrance of BRCA2 were markedly lower
at younger ages, BRCA2 mutations could be more com-
mon in the population.
Although this was primarily a study based on linkage
rather than on mutation data, we also performed some
heterogeneity analyses incorporating BRCA1 mutation
data. The main aim of these additional analyses was to
ensure that no serious biases had been introduced by
selective typing of BRCA2 markers on the basis of
BRCA1 mutation status. Intuitively, such bias seem un-
likely, since only a small proportion of data could have
been influenced, and the analyses incorporating the mu-
tation data obtained essentially the same estimates as
were obtained by the analyses without mutation data.
As a by-product of these analyses, we were able to obtain
an estimate of the sensitivity of the mutation testing used
in this study. Inevitably, this is a quite crude analysis,
since different investigating groups used different screen-
ing techniques. Assuming that all methods (other than
screening less than the whole of the gene) were equally
sensitive, we estimated an identification probability of
63% (95% Cl 51%–77%). In this data set there was no
evidence that sensitivity differed between sequencing and
other methods. The obvious explanation for this rela-
tively low sensitivity estimate, even for direct sequencing,
is that a substantial fraction of BRCA1 alterations occur
outside the coding sequence and splice sites. This ex-
planation is supported by the observation that no mu-
tation has been identified for a relatively high proportion
of families where the disease is clearly linked to BRCA1.
Of the 33 families with a LOD score 11.0 for linkage
to BRCA1, 30 had been screened for a BRCA1mutation.
On the basis of the posterior probabilities in these fam-
ilies, one would predict that 29.3 (98%) of cases should
be due to BRCA1. In fact, 21 mutations (70%) were
found (3 of 6 tested by direct sequencing, 12 of 17 tested
by CDGE, CSGE, DSDI/PTT, or SSCP-HA, and 6 of 7
tested by SSCP alone). Of the nine families without mu-
tations, two (UTAH 2035 and IARC 2090) were shown
to have loss of the entire BRCA1 transcript in cDNA,
and one (IARC 1816) was found to have loss of exon
18 in transcript, but with no splice-site alteration. These
families are therefore false negatives, according to the
usual DNA-based testing methods. The true proportion
of families with inferred regulatory mutations may be
much higher, since cDNA testing is not always possible
or informative. Other possible explanations for the
“missing” mutations would include large deletions, pro-
moter-sequence alterations, or simply a coding-sequence
alteration that was missed.
We were able to estimate the penetrance of BRCA2
in families with a known mutation and to provide evi-
dence for a high lifetime risk of breast or ovarian cancer:
our overall estimates were 29% (95% Cl 9%–44%) by
age 50 years and 88% (95% Cl 48%–97%) by age 70
years, the majority of which is attributable to breast
cancer. Although not significantly different, the esti-
mated breast cancer risk at younger ages was somewhat
lower in BRCA2 mutation carriers compared with
BRCA1 mutation carriers; 30% (76 of 250) of breast
cancers at age !70 years in the 36 families with a germ-
line BRCA2 mutation were diagnosed at age !40 years
and 73% (182 of 250) were diagnosed at age !50 years,
compared with 50% (210 of 416) diagnosed at age !40
years and 80% (333 of 416) diagnosed at age !50 years
in the 64 families with a germ-line BRCA1 mutation.
The overall risks of ovarian cancer (7% by age 60 years
and 27% by age 70 years) are lower than the corre-
sponding estimates for BRCA1 that had been obtained
by previous consortium analyses (31% by age 60 and
42% by age 70 years [Easton et al. 1993; Narod et al.
1995b]; and 30% by age 60 years and 63% by age 70
years [Easton et al. 1995]), although they still are sub-
stantially elevated above the risks in the general popu-
lation. This is entirely consistent with the heterogeneity
results showing that BRCA2 is responsible for a
smaller—but still significant—fraction of breast-ovarian
cancer families than is due to BRCA1.
Our penetrance estimates assumed that all mutations
conferred the same risks, which is likely to be an over-
simplification. Gayther et al. (1997) found evidence for
an increased risk of ovarian cancer, relative to the risk
of breast cancer, associated with mutations in the central
portion of BRCA2 (the OCCR), compared with muta-
tions outside this region. Our study provides some sup-
port for this genotype-phenotype correlation, in that
higher risks of ovarian cancer—but similar risks of
breast cancer—were estimated for BRCA2 mutations in
the OCCR, compared with mutations outside it.
Recently Struewing et al. (1997) estimated the pene-
trance of BRCA1 and BRCA2 mutations on the basis
of the family histories of 120 Ashkenazi Jewish volun-
teers found to have any of the three founder mutations
common in this population. In carriers of the 6174delT
mutation, which lies within the OCCR, they estimated
a breast cancer risk of ∼50% by age 70 years and an
ovarian cancer risk of ∼10% by age 60 years and 18%
by age 70 years. These estimates are somewhat lower
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than the estimates derived in the present study, but they
are not inconsistent, given the wide confidence limits.
In this study, we have not attempted to estimate the
risk of male breast cancer in BRCA2 families. The max-
imum-LOD-score approach would not provide a precise
estimate, because the penetrance is clearly quite low.
Using the two largest BRCA2 families with linkage (fam-
ilies UTAH 107 and CRC 186) Easton et al. (1997)
estimated the cumulative risk of male breast cancer in
BRCA2 carriers to be 6% by age 70 years, but this was
based on only four observed cases and hence is very
imprecise. There is also circumstantial evidence of var-
iation in male breast cancer risk; whereas the large ma-
jority (19 of 26) of “male breast cancer” families in this
study contain only one male case, two families contained
four cases each. In both of these families, BRCA2 mu-
tations have been identified. This variation in risk is
likely to be due, at least in part, to modifying factors,
since both families have mutations identical to those in
large breast cancer families that do not have male breast
cancer cases.
In addition to the risks of breast and ovarian cancer,
previous studies have suggested an increased risk of a
number of other cancers in BRCA2 carriers, including
prostate cancer (Tulinius et al. 1992), pancreatic (Phelan
et al. 1996), and ocular melanoma (Easton et al. 1997).
The risks of other cancers in the collaborative BCLC
data set are currently being evaluated.
The penetrance estimates provided by this study, to-
gether with the comparable estimates for BRCA1 car-
riers, should be useful for genetic counseling of mutation
carriers. Such estimates must always be used with cau-
tion, however. They are appropriate for counseling in
multiple-case families but may not apply to mutation
carriers with little or no family history. The risks to such
individuals could be lower than those estimated here,
either if there is risk variation between mutations, or if
modifying genes or other familial risk factors strongly
influence penetrance.
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Appendix A
Heterogeneity Analysis
Linkage analyses were performed by means of the
FASTLINK version of the LINKAGE program (Lathrop
et al. 1984; Cottingham et al. 1993). The CASH model
was modified to assume that the incidence of breast can-
cer in gene carriers age x70 years was the same as in
carriers age 60–69 years. The risks in noncarrier females
were assumed to follow population rates for breast and
ovarian cancer for England andWales. (All families were
from western European or North American populations
that have similar breast and ovarian cancer incidence
rates.) For implementation in LINKAGE, 21 liability
classes were constructed, allowing for seven age groups
and three phenotypes (unaffected, affected with breast
cancer, and affected with ovarian cancer). Individuals
with both breast and ovarian primary cancers were
treated as if they were affected with breast cancer at age
!30 years, in order to maximize their probability of be-
ing gene carriers. Males with breast cancer were also
treated as if they were females affected at age !30 years,
because of the rarity of male breast cancer. All unaffected
males were treated as they were unaffected females of
age !30 years, which is approximately equivalent to be-
ing of unknown disease status.
For most families, multipoint LOD scores for linkage
to BRCA1 and BRCA2 were computed by use of two
flanking markers and the disease. A small minority of
families contained consanguineous or marriage loops,
and these were broken if this resulted in no loss of in-
formation, but, when a loop had to be retained, the most
informative marker on each chromosome was used in a
two-point analysis. BRCA1 was assumed to lie either
midway between THRA1 and D17S579 (1.3 cM from
THRA1 on the male genetic map, with a 2:1 female:
male genetic-distance ratio) or at D17S855. BRCA2 was
assumed to lie 1 cM distal to D13S260 and 2 cM prox-
imal to D13S267.
Estimates of proportions of families with disease due
to BRCA1 and BRCA2 were obtained by maximization
of the heterogeneity LOD score,
LOD(a ,a )1 1
LOD LOD1 2 Slog [a 10 (v ) a 10 (v ),10 1 1 2 2
 (1 a  a )] (A1)1 2
with respect to a1 and a2, where a1 and a2 are the re-
spective proportions of families with disease linked to
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BRCA1 and BRCA2. The proportion of families with
disease due to other high-penetrance genes is estimated
by . v1 is the vector of recombination frac-1 a  a1 2
tions between the 17q markers and BRCA1, and v2 is
the vector of recombination fractions between the 13q
markers and BRCA2. LOD1(v1) and LOD2(v2) are the
multipoint LOD scores for linkage to BRCA1 and
BRCA2, respectively. Summation is over all families.
Maximizing this heterogeneity LOD score provides
consistent estimates for a1 and a2. This is true despite
the fact that families showing strong evidence for linkage
to BRCA1 were sometimes not typed for BRCA2 mark-
ers. The reasoning behind this is as follows. Equation
(A1) may be rewritten as
LOD(a ,a )1 2
 Slog L(D,M ,M /v , v ,a ,a )10 1 2 1 2 1 2
 Slog L(D,M ,M /1/2, 1/2)10 1 2
 Slog L(D,M ,M /D, v , v ,a ,a )10 1 2 1 2 1 2
 Slog L(M ,M ) ,10 1 2
where D represents the disease phenotypes and M1 and
M2 represent the observed marker genotypes. Thus max-
imizing the LOD score is equivalent to maximizing the
likelihood of all marker and disease phenotypes, con-
ditional on the disease phenotypes (Elston 1995). This,
in turn, may be written as
LOD(a ,a )1 2
 Slog L(D,M /D, v ,a )10 1 1 1
 Slog L(D,M ,M /D,M v , v a ,a )10 1 2 1 1 2 1 2
 Slog L(M ,M ) .10 1 2
The first term is a conditional log likelihood for the
markers at the BRCA1 locus, and it therefore gives con-
sistent estimates of a1. The second term is a conditional
log likelihood for the BRCA2 markers, conditional on
the disease status and the BRCA1 marker genotypes,
which is therefore a valid log likelihood leading to con-
sistent estimates of a1 and a2, even though there is some
selection based on M1. The third term is simply a con-
stant. Maximizing LOD (a1,a2) will therefore give con-
sistent estimates for a1 and a2 (by the usual argument
that, since the expected derivative of each term on the
right-hand side of the equation is zero at the true values
of a1 and a2, since each is a valid log likelihood, this
must also be true of the sum).
Analyses allowing BRCA1 to confer a higher pene-
trance (the “BRCA1 model”) were based on maximi-
zation of the LOD score,
LOD(a ,a )1 2
 Slog [a L (D,M ,M /v , 1/2)10 1 1 1 2 1
 a L (D,M ,M /1/2, v )2 2 1 2 2
 (1 a  a )L (D,M ,M /1/2, 1/2)]1 2 2 1 2
 Slog [a L (D,M ,M /1/2, 1/2)10 1 1 1 2
 a L (D,M ,M /1/2, 1/2)2 2 1 2
 (1 a  a )L (D,M ,M /1/2, 1/2)] ,1 2 2 1 2
with respect to a1, the proportion of BRCA1 mutations
as a proportion of all high-risk mutations, and a2, the
proportion of BRCA2 mutations as a proportion of all
high-risk mutations, L1 represents the likelihood for a
family under the BRCA1 model, and L2 represents the
likelihood under the CASH model. The relative fre-
quency of mutations in high-risk genes other than
BRCA1 and BRCA2 is estimated by . Sum-1 a  a1 2
mation is over all families.
Dividing the numerator and the denominator by
L2(D,M1,M2/1/2, 1/2) allows simplification to
LOD(a ,a )1 2
LOD (v )G1 1 Slog [a 1010 1
LOD (v )2 2 a 10  (1 a  a )]2 1 2
G Slog [a 10  a  (1 a  a )] . (A2)10 1 2 1 2
LOD1(v)1 is the multipoint LOD score for linkage to
BRCA1, computed under the BRCA1 model, and
LOD2(v)2 is the multipoint LOD score for linkage to
BRCA2, computed under the CASH model. G 
; that is, G is the log of the ratio oflog [L (D)/L (D)]10 1 2
the likelihood of the disease phenotypes in the family
under the BRCA1 model to the likelihood of the disease
phenotypes under the CASH model. (For practical pur-
poses, L1(D)/L2(D) is the same as L1(D,M/1/2)/L2(D,M/
1/2); hence, both numerator and denominator may be
computed in LINKAGE, with the same marker data but
with different models; we used the 17q marker typings
for which we had already computed the numerator and
denominator.)
a1, a2, and no longer estimate the pro-1 a  a1 2
portions of families with disease due to BRCA1, BRCA2,
and other genes, since these depend on the genes’ pen-
etrances as well as on their frequencies. For each family,
the posterior probabilities p1 (i.e., of segregating a
BRCA1 mutation), p2 (i.e., of segregating a BRCA2 mu-
tation), and p3 (i.e., of segregating a mutation in another
high-risk gene) were therefore computed, where
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LOD (v )G LOD (v )G1 1 1 1p  a 10 /[a 101 1 1
LOD (v )2 2 a 10  (1 a  a )] ,2 1 2
LOD (v ) LOD (v )G2 2 1 1p  a 10 /[a 102 2 1
LOD (v )2 2 a 10  (1 a  a )] ,2 1 2
and . The proportion of families due top  1 p  p3 1 2
each gene was then estimated as the average of the cor-
responding posterior probabilities.
Appendix B
Heterogeneity Analysis Incorporating BRCA1 Mutation
Data
Parameters a1, a2, and d were estimated by joint max-
imization of a likelihood incorporating both linkage and
mutation data. Under the assumption that the CASH
model applies to all genes, a family with an identified
mutation contributes to the total like-LOD (v )1 1log (a d10 )10 1
lihood expression, a family in which the mutation has
been looked for but was not found contributes
LOD (v )1 1log [a (1 d)1010 1
LOD (v )2 2 a 10  (1 a  a )] ,2 1 2
and a family in which mutation testing has not been
performed contributes as previously described (see eq.
[A1].
The parameter d can similarly be introduced into the
analysis, allowing BRCA1 to confer a higher penetrance.
A family with an identified mutation then contributes
LOD (v )G1 1log (a d10 )10 1
G log [a 10  a  (1 a  a )]10 1 2 1 2
to the total likelihood expression. A family in which the
mutation has been looked for but has not been found
contributes
LOD (v )G1 1log [a (1 d)1010 1
LOD (v )2 2 a 10  (1 a  a )]2 1 2
G log [a 10  a  (1 a  a )]10 1 2 1 2
to the total likelihood, and a family in which mutation
testing has not been performed contributes as described
previously (see eq. [A2]).
Confidence intervals for the parameters a1, a2, (1
), and d were computed by comparing the dif-a  a1 2
ference in loge likelihoods for different values of a1, a2,
( ), and d, respectively, and maximizing over1 a  a1 2
the other parameters, to a x2 distribution on 1 df. To
compute the upper and lower confidence limits on the
proportion of families with disease attributable to a gene
(e.g., BRCA1), we used the upper and lower confidence
limits, respectively, on a1, with the maximum-likelihood
estimate for a2, given a1, and with computed posterior
probabilities of linkage to each gene, as described above.
Appendix C
Estimation of the Penetrance of BRCA2
Computations were performed with a modified ver-
sion of the ILINK program (Lathrop et al. 1984);
D13S267 typings were used, since the computer time
that would be required for maximization over multi-
point data was prohibitive. Incidence rates in noncarriers
were fixed at the population rates for England and
Wales. Rates in carriers were modeled under the as-
sumption of a separate parameter for the ratio of the
incidences in gene carriers versus the incidences for car-
riers in the CASH model, for each of five age groups
(20–29 years, 30-39 years, 40–49 years, 50–59 years,
and 60–69 years). Follow-up of all females was censored
at age 70 years. Men were included in the liability class
for the 20–29-years-old age group. Male breast cancer
cases were therefore assumed to be likely to be gene
carriers, regardless of age at diagnosis, and no attempt
was made to estimate the penetrance for male breast
cancer. The overall penetrance, defined as risk of breast
or ovarian cancer, was modeled by defining age at onset
as the age at diagnosis of the first cancer (either breast
or ovarian). Estimates of breast and ovarian cancer in-
cidence were then obtained by dividing the overall in-
cidence rate in each age group by the observed age-
specific proportions of breast and ovarian cancer.
The penetrance of BRCA2, as based on families with
six or more breast cancers, was estimated by maximi-
zation of the LOD score
( )LOD g
LOD v LOD v F( ) ( )1 1 2 2( )Slog g10  1 g 1010 [ ]
F( )Slog g 1 g 10 ,[ ]10
where g is the proportion of high-risk mutations that
are BRCA1 mutations. The proportion of high-risk mu-
tations that are BRCA2 mutations is then forced to be
( ). LOD1(v1) is the LOD score at BRCA1, under1 g
the BRCA1 model (and is fixed), and LOD2(v2) is the
LOD score at BRCA2, under the model estimated for
BRCA2 (which is maximized over different penetrance
functions). , where L1(D) is theF  log [L (D)/L (D)]10 1 2
likelihood of the disease phenotypes under the BRCA1
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model (and is fixed) and L2(D) is the likelihood of the
disease phenotypes under the BRCA2 model (and has
to be recomputed at each iteration, as the model
changes). (In practice we computed F  log10[L1(D,M/
1/2)/L2(D,M/1/2)] by using MLINK with D13S267 typ-
ings [when these were available] or, otherwise, a dummy
marker with complete typing [for speed].)
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